Virtu Financial LLC Takes Position in argenx SE (NASDAQ:ARGX)

Virtu Financial LLC acquired a new position in argenx SE (NASDAQ:ARGX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,184 shares of the company’s stock, valued at approximately $728,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC raised its position in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of argenx by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after acquiring an additional 10,975 shares during the period. Wellington Management Group LLP lifted its position in argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after purchasing an additional 55,617 shares during the period. Alkeon Capital Management LLC boosted its stake in argenx by 15.0% during the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARGX. Robert W. Baird upped their price objective on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Piper Sandler raised their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Wells Fargo & Company lifted their price objective on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. JMP Securities increased their target price on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Finally, Guggenheim lifted their price target on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Stock Down 1.1 %

Shares of NASDAQ:ARGX opened at $607.95 on Tuesday. The firm has a fifty day moving average of $633.44 and a two-hundred day moving average of $600.67. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The firm has a market capitalization of $36.94 billion, a P/E ratio of -690.85 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Equities research analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.